Renalytix (Renalytix) Total Liabilities : $19.88 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Renalytix Total Liabilities?

Renalytix's Total Liabilities for the quarter that ended in Mar. 2024 was $19.88 Mil.

Renalytix's quarterly Total Liabilities declined from Sep. 2023 ($21.03 Mil) to Dec. 2023 ($19.21 Mil) but then increased from Dec. 2023 ($19.21 Mil) to Mar. 2024 ($19.88 Mil).

Renalytix's annual Total Liabilities increased from Jun. 2021 ($7.48 Mil) to Jun. 2022 ($19.46 Mil) and increased from Jun. 2022 ($19.46 Mil) to Jun. 2023 ($23.66 Mil).

Renalytix Total Liabilities Historical Data

The historical data trend for Renalytix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Total Liabilities Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

1.15

5.34

7.48

19.46

23.66

Renalytix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															21.71	23.66	21.03	19.21	19.88

Renalytix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Renalytix's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16.136	+	(7.526	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	23.66

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	30.629	-	6.967
	=	23.66

Renalytix's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.988	+	(4.892	+	-8.8817841970013E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	19.88

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	8.769	-	-11.111
	=	19.88

Renalytix Total Liabilities Related Terms

Thank you for viewing the detailed overview of Renalytix's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (Renalytix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RTNXF:USA RENX:UK 2O9A:Germany 2O9A:Germany 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Executives

Howard Jr Doran	officer: Chief Business Officer	C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie	director	85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain	officer: President	NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc.	10 percent owner	150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai	10 percent owner	1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills	director, 10 percent owner	C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling	officer: Chief Financial Officer	C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc.	10 percent owner	ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount	10 percent owner	ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming	director, officer: Chief Technical Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough	director, officer: Chief Executive Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE